Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of ...

(HealthDay News) — For patients with high-risk, early-stage estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer (BC), adding nivolumab to ...

Nivolumab plus cabozantinib provides long-term benefits over sunitinib in advanced RCC, according to final results from CheckMate 9ER.

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Opdualag is a fixed-dose combination of nivolumab, a programmed death receptor-1 blocking antibody, and relatlimab, a lymphocyte activation gene 3 blocking antibody.

The combination therapy failed to beat out the company’s other cancer therapy, Opdivo, in patients living with melanomas.

During a Case-Based Roundtable® event, Julie R. Brahmer, MD, MSC, reviewed the CheckMate 9LA, KEYNOTE-407, and POSEIDON ...

Patients may require life-long monitoring and a collaborative engagement with subspecialists to keep well in the long -term,” ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

Opdivo plus Cometyx resulted in a significant progression and survival benefits compared with Sutent in the first-line treatment of patients with advanced renal cell carcinoma.

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Health systems are facing hurdles to implementing new and effective metastatic urothelial carcinoma (mUC) therapies into ...